Literature DB >> 11438828

Successful treatment of intravascular malignant lymphomatosis with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

M Koizumi1, M Nishimura, A Yokota, S Munekata, T Kobayashi, Y Saito.   

Abstract

Intravascular malignant lymphocytosis (IML) is a rare systemic disease characterized by proliferation of malignant B (rarely T) lymphoid cells within the lumina of small arteries, veins, and capillaries. Diagnosis requires skin, liver, renal, meningeal, or brain biopsy, but is rarely made ante mortem. In this report, we describe a patient who had an ante mortem diagnosis of IML as a result of a skin biopsy. Autologous peripheral blood stem cell transplantation (auto-PBSCT) was successfully performed after chemotherapy. The patient has survived for more than 30 months since the onset of the disease and maintains complete remission on the 450th day post PBSCT. To our knowledge, this is the first case of IML treated by auto-PBSCT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438828     DOI: 10.1038/sj.bmt.1703038

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  Intravascular lymphomatosis and intracerebral haemorrhage.

Authors:  Maria Grazia Passarin; Patrick Y Wen; Emanuela Vattemi; Ebba Buffone; Claudio Ghimenton; Lamberto Bontempini; Sarah Ottaviani; Anna Maria Musso; Rebecca Pedersini
Journal:  Neurol Sci       Date:  2010-06-02       Impact factor: 3.307

2.  Intravascular lymphomatosis of the nervous system.

Authors:  M Szots; A Szomor; F Kover; L Pajor; S Komoly; E Kalman; E Gomori; Z Illes
Journal:  J Neurol       Date:  2008-07-28       Impact factor: 4.849

3.  Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience.

Authors:  J Meissner; H Finel; S Dietrich; A Boumendil; E Kanfer; G Laboure; M Abecasis; J Cornelissen; J Delage; J Finke; U Hess; H Ludwig; M Mohty; T Pabst; P Pioltelli; S Robinson; P Samaras; S Montoto; P Dreger
Journal:  Bone Marrow Transplant       Date:  2016-12-19       Impact factor: 5.483

4.  Long-term remission after high-dose chemotherapy followed by auto-SCT as consolidation for intravascular large B-cell lymphoma.

Authors:  K Kato; Y Ohno; T Kamimura; H Kusumoto; T Tochigi; F Jinnouchi; K Kohno; T Kuriyama; H Henzan; K Takase; I Kawano; M Kadowaki; R Nawata; T Muta; T Eto; H Iawasaki; K Ohshima; T Miyamoto; K Akashi
Journal:  Bone Marrow Transplant       Date:  2014-08-18       Impact factor: 5.483

Review 5.  A new approach to the diagnosis and treatment of intravascular lymphoma.

Authors:  Joachim M Baehring; Janina Longtine; Fred H Hochberg
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

Review 6.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

7.  Signs of rapidly progressive dementia in a case of intravascular lymphomatosis.

Authors:  R Albrecht; B Krebs; E Reusche; M Nagel; R Lencer; H A Kretzschmar
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-24       Impact factor: 5.270

Review 8.  Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement.

Authors:  Thomas Breakell; Heidi Waibel; Stefan Schliep; Barbara Ferstl; Michael Erdmann; Carola Berking; Markus V Heppt
Journal:  Curr Oncol       Date:  2022-04-19       Impact factor: 3.109

9.  A Rare Case of Intravascular Large B-cell Lymphoma Presenting With Bilateral Ophthalmoplegia, Along With a Literature Review.

Authors:  James Allen; Anam Shaikh; Karrah Laurent-Ariot; Matthew Merola
Journal:  Cureus       Date:  2022-06-14

10.  Intravascular lymphomatosis of the brain in a patient with myelodysplastic syndrome.

Authors:  Gregorius J Sips; Colum F Amory; Bradley N Delman; George M Kleinman; Lewis R Lipsey; Stanley Tuhrim
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.